Course Description

  • WHO: This course provides pharmacists, student pharmacists, members of academia, industry and government with the skills necessary to develop and implement a point-of-care test and treat program for minor, nonchronic health conditions, such as influenza, Group A streptococcus, and minor, uncomplicated infections, within the framework of an established written protocol with a supervising physician.
  • WHY: There is a recognized need for pharmacists to collaboratively improve patient access to care through the use of point-of-care tests and treatment.
  • HOW: The course’s 20 hours of continuing education (12 hours of home study and 8 hours of live training) will cover information on the targeted disease states, the physical assessment of a patient presenting to a pharmacist, point-of-care tests and how to establish a point-of-care testing service and screening for and treatment of minor, nonchronic health conditions.
  • WHEN: Please visit the upcoming trainings webpage for more information.

Program Course

Self-Study Modules (12 Hours)

Module 1: Overview of Testing or Screening for and Treatment of Minor, Nonchronic Health Conditions

Length: 2 hours

  • Identify opportunities for pharmacists to utilize testing or screening for and the treatment of minor, nonchronic health conditions within the framework of an established written protocol with a supervising physician.
  • Identify the Florida requirements for a written protocol with a supervising physician.
  • Describe the required elements of a written protocol between a physician and pharmacist for test and treat.
  • Summarize the findings from recent collaborative research projects utilizing Point-of-Care test (POCT), protocols or Collaborative Practice Agreements (CPAs) for treatment for influenza, Streptococcus and minor, nonchronic health conditions and minor uncomplicated infections.

Module 2:  Assessing Test Performance and Determining How to Use a Test Appropriately

Length:  1 hour

  • Summarize the Clinical Laboratory Improvement Amendments (CLIA) as they pertain to pharmacy point-of-care testing (POCT).
  • Differentiate between FDA approval and Emergency Use Authorization (EUA)
  • Describe the process of obtaining a Clinical Laboratory Improvement Amendments (CLIA) certificate of waiver in Florida and regulatory requirements for pharmacies functioning as a CLIA-waived laboratory.
  • List elements of Good Laboratory Practices recommended for CLIA-waived testing sites.
  • Assess test performance and determine how to use a test appropriately.

Module 3: Disease States for Point-of-Care Testing or Screening for and Treatment of Minor, Nonchronic Health Conditions or Screening for and Treatment of Minor, Nonchronic Health Conditions – Infectious Diseases

Length: 3.5 hours

  • Summarize the pathophysiology, clinical presentation, nonpharmacologic treatment, pharmacologic treatment, patient counseling and special population’s considerations of the following disease states or conditions.
    • Influenza
    • Streptococcus
    • Minor, uncomplicated infections.
      • Herpes Simplex Labialis (HSL) Cold Sores/Fever Blisters
      • Uncomplicated cystitis

Module 4: Disease States for Point-of-Care Testing or Screening for and Treatment of Minor, Nonchronic Health Conditions or Screening for and Treatment of Minor, Nonchronic Health Conditions – Skin Conditions

Length: 2.5 hours

  • Summarize the pathophysiology, clinical presentation, nonpharmacologic treatment, pharmacologic treatment, patient counseling and special population’s considerations of the following disease states or conditions.
    Skin Conditions

    • Xerosis and Atopic Dermatitis
    • Scaley Dermatosis
    • Contact Dermatitis
    • Insect Stings and Bites
    • Lice
    • Acne
    • Minor Burns and Wounds
    • Fungal Skin Infections

Module 5: Brief overview of other Point-of-Care Testing (no minor ailments or treatment authority)

Length: 2 hours

  • Explain the pathophysiology, clinical presentation, nonpharmacologic treatment, pharmacologic treatment, patient counseling and special population’s considerations of the following disease states:
    • Other Respiratory infections (e.g., Respiratory Syncytial Virus, Coronaviruses)
    • HIV – PrEP and PEP
    • Hepatitis C Virus
    • Sexually Transmitted Infections (e.g., syphilis, chlamydia, and gonorrhea)
    • Conjunctivitis
    • Helicobacter pylori
    • Lyme Disease
    • Infectious mononucleosis

Module 6: Use of Point-of-Care Tests to Promote Antimicrobial Stewardship (AS)

Length: 0.5 hours

  • Define and summarize antimicrobial stewardship.
  • Identify ways that pharmacists can practice stewardship and reduce antimicrobial resistance.
  • Discuss how point-of care testing (POCT) can reduce unnecessary antibiotic use and contribute to a pharmacy’s stewardship program.

Module 7: Collaboration with State and Local Health Departments

Length: 0.5 hours

  • Identify the role and responsibilities of state and local health departments, especially as they relate to disease surveillance and reporting.
  • Outline steps to develop partnerships with state and local health departments around point-of-care testing (POCT) and treatment.
  • Summarize the benefits and value of partnering with state and local health departments.

Live/Virtual Training Session (8 hours)

Module 1: Overview of Testing or Screening for and Treatment of Minor, Nonchronic Health Conditions

Length: 0.5 hours

  • Discuss key points from the self-study modules.
  • Utilize testing or screening for and the treatment of minor, nonchronic health conditions within the frameworks of an established written protocol with a supervising physician.
  • Describe how to implement testing or screening for and minor treatment of minor nonchronic health conditions services in your practice.

Module 2: Florida Statutes and Regulations

Length: 1 hour

  • Describe the statutes and regulations applicable to testing or screening for and treatment of minor, nonchronic health conditions.
  • Identify the signage, reporting, documentation and reporting requirements to patients, other health care providers and public health agencies for services provided.
  • Discuss the required components in Florida law for protocol development.
  • Explain the mandatory continuing education required by Florida law to provide testing or screening for and treatment of minor, nonchronic health conditions.

Module 3: Physical Assessment
Length: 1.5 hours

  • Discuss the value and limitations of various physical assessment procedures, including body temperature, pulse, blood pressure, respiratory rate, cervical lymph node inspection, throat examination, and physical inspection.
  • Demonstrate the procedures for conducting a systematic physical assessment and identify normal and critical findings.
  • Interpret physical assessment data and recognize limitations of the data.
  • Document patient assessment results.

Module 4: Specimen, Test Performance and Results
Length: 1.5 hour

  • Describe the basic process of specimen collection for point-of-care testing (POCT).
  • Identify a patient specimen that would be appropriate for a Clinical Laboratory Improvement Amendments (CLIA)-waived POCT.
  • Describe factors that can influence test performance.
  • Explain how test performance influences interpretation of test results.
  • Demonstrate the technique involved for the specimen collection types discussed.

Module 5: Application of the Florida Requirements for Testing, Screening and Treatment of Minor Nonchronic Health Conditions (case studies and practical applications)
Length: 3.5 hours

  • Identify specific categories of patients who the pharmacist is authorized to test or screen for and treat minor, nonchronic health conditions.
  • Describe the physician’s instructions for obtaining relevant patient medical history for the purpose of identifying disqualifying health conditions, adverse reactions, and contraindications to the approved course of treatment.
  • Create a process and schedule for the physician to review the pharmacist’s actions under the protocol.
  • Identify a process and schedule for the pharmacist to notify the physician of the patient’s condition, tests administered, test results, and course of treatment.
  • Demonstrate ability to apply for CLIA waiver.
  • Develop a written protocol that includes all legally required components for legally authorized disease states and appropriate lab testing required.
  • Apply test and treat protocol information to patient-specific cases based on common pharmacy-based patient interactions.

Additional Information

Agenda
CE Info
Developer Bios
Disclaimers
Host a Training
Upcoming Trainings

Home